Virtual Library

Start Your Search

Chokaew Tovanabutra



Author of

  • +

    P1.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 947)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.15-30 - Survival of Patients with Advanced NSCLC Treated with First-Generation EGFR-TKIs at a Cancer Hospital in Thailand, 2011-2016 (ID 11147)

      16:45 - 18:00  |  Author(s): Chokaew Tovanabutra

      • Abstract
      • Slides

      Background

      This study was to find the survival in advanced NSCLC patients treated with an EGFR-TKI in a real-life practice.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      The researcher conducted this retrospective study by review medical records in stage IIIB-IV NSCLC patients treated with first-generation EGFR-TKIs at Chonburi Cancer Hospital from January, 2011 to December, 2016 and follow up until December, 2017.

      4c3880bb027f159e801041b1021e88e8 Result

      This study enrolled 50 patients with median follow up time 16.78 months. The median age of patients was 58.5. There were female (46%), non-smoking (62%) and adenocarcinoma (90%). The patients received an EGFR-TKI by purchase by themselves (52%), reimbursement system (32%) and compassionate use (14%), additionally Eastern Cooperative Oncologic Group (ECOG) performance statuses were 0-1 (54%), 2-4 (28%) and non-available (NA) (18%).Treatment responses stratified by line of therapy and EGFR status were shown (table)

      EGFR-TKIs

      treatment

      EGFR

      mutation status

      Response to

      an EGFR-TKI

      Total

      (N)

      PR SD PD NA

      First-line (1L)+ maintenace (MN)

      (n=16+2)

      Sensitive 3 1 0 0 4
      Wild-type 0 2 0 0 2
      Unknown 4 4 2 2 12

      Second-line (2L)

      (n=18)

      Sensitive 1 3 0 0 4
      Wild-type 0 0 1 1 2
      Unknown 5 2 4 1 12

      Third-ine or more (>/=3L)

      (n=14)

      Sensitive 2 1 0 0 3
      Wild-type 0 0 1 1 2
      Unknown 1 1 5 2 9
      Total (N) 16 14 13 7 50

      The overall survivals (OS) of the patient receiving an EGFR-TKI as 1L or MN (n=18), 2L (n=18) and >/=3L (n=14) were 15.86 (95%CI, 10.26-21.46), 10.87 (95%CI, 0.00-28.29) and 20.23 (95%CI, 6.26-34.21) months (p=0.392), respectively. Regarding EGFR status, the OS of patients with EGFR sensitive mutation (n=11), wild-type (n=6) and unknown (n=33) were 30.75 (95% CI, 13.76-47.74), 7.91 (95% CI, 0.00-20.45) and 13.99 (95%CI, 9.17-18.82) months (p=0.086), respectively.

      Multivariate analysis indicated that age >/=70 years old (p=0.047) ,current or former smoking (p=0.012), ECOG performance status 2-4 or NA (p<0.001), received EGFR-TKIs by payment (p=0.033) or compassionate use (p<0.001) were the unfavorable prognostic factors for the OS.

      8eea62084ca7e541d918e823422bd82e Conclusion

      The OS of the patients harboring EGFR sensitive mutation at our hospital was comparable to those of other pivotal studies. Clearly, patients harboring EGFR wild-type had the OS much shorter than those of the sensitive mutation group. In real practice at that time, two-third of patients still have not been proved their EGFR statuses before starting an EGFR-TKI and often received it as second-line or more.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.